Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 910 JPY -0.47% Market Closed
Market Cap: 4.8T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Gross Margin
Otsuka Holdings Co Ltd

71.4%
Current
68%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
71.4%
=
Gross Profit
1.6T
/
Revenue
2.3T

Gross Margin Across Competitors

Country JP
Market Cap 4.8T JPY
Gross Margin
71%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.8T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being. For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.

Intrinsic Value
9 473.82 JPY
Undervaluation 6%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
71.4%
=
Gross Profit
1.6T
/
Revenue
2.3T
What is the Gross Margin of Otsuka Holdings Co Ltd?

Based on Otsuka Holdings Co Ltd's most recent financial statements, the company has Gross Margin of 71.4%.